2018 Competitor Analysis: PRAME-Targeted Immunotherapy - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jun 13, 2018--The “Competitor Analysis: PRAME-Targeted Immunotherapy” report has been added to ResearchAndMarkets.com’s offering.
This Competitive Intelligence report analyzes the competitive field of PRAME-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant data.
The report includes a compilation of currently active projects in research and development of passive and active immunotherapy and adoptive cell therapy targeting PRAME. In addition, the report lists company- and institution-specific R&D pipelines of PRAME-Targeted Immunotherapies.
PRAME (preferentially expressed antigen in melanoma), a member of the cancer-testis antigen family, has been shown to have increased expression in solid tumors. PRAME was first identified as a tumor-associated antigen through analysis of the specificity of tumor-reactive T-cell clones derived from a patient with metastatic cutaneous melanoma.
Subsequently, it has been shown that PRAME is expressed in many malignant neoplasms, including cutaneous melanoma, breast carcinoma, non-small cell lung cancer, and leukemia, whereas normal healthy tissues express minimal or no PRAME, with the exception of the testis and endometrium.
It was shown that PRAME-specific CD8+ T cells isolated from healthy individuals and patients with advanced melanoma were able to recognize and lyse cells expressing HLA class I and high levels of PRAME. Thus, PRAME is a potential candidate for cancer immunotherapy because it is expressed by a variety of tumours and can induce T-cell immune responses.
Competitor projects are listed in a tabular format providing information on:Drug Codes Target/Mechanism of Action Class of Compound Company Product Category Indication R&D Stage Additional comments with a hyperlink leading to the source of information
Key Topics Covered
1. PRAME-Targeted ImmunotherapyPRAME-Targeted Selective and Multi-Antigen Cancer Vaccines PRAME-Selective Cellular & Recombinant Immunotherapies PRAME-Specific, Multi-Target Adoptive Cell Therapy
2. Corporate & Institutional PRAME Immunotherapy R&D Pipelines
For more information about this report visit https://www.researchandmarkets.com/research/n5txrb/2018_competitor?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180613006278/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Oncology Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/13/2018 06:03 PM/DISC: 06/13/2018 06:03 PM